HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · Real-Time Price · USD
1.860
+0.080 (4.49%)
At close: Jan 14, 2025, 4:00 PM
1.870
+0.010 (0.54%)
After-hours: Jan 14, 2025, 4:02 PM EST
HOOKIPA Pharma Revenue
HOOKIPA Pharma had revenue of $4.70M in the quarter ending September 30, 2024, a decrease of -31.51%. This brings the company's revenue in the last twelve months to $50.00M, up 143.30% year-over-year. In the year 2023, HOOKIPA Pharma had annual revenue of $20.13M with 41.27% growth.
Revenue (ttm)
$50.00M
Revenue Growth
+143.30%
P/S Ratio
0.45
Revenue / Employee
$279,324
Employees
179
Market Cap
22.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
HOOK News
- 5 days ago - Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - GlobeNewsWire
- 6 days ago - HOOKIPA Pharma Inc - FORM 8 (OPD) - GlobeNewsWire
- 7 days ago - HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - GlobeNewsWire
- 9 days ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment - GlobeNewsWire
- 13 days ago - Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - GlobeNewsWire